within Pharmacolibrary.Drugs.V_Various.V09A_CentralNervousSystem.V09AX06_Florbetaben18f;
model Florbetaben18f 
   extends Pharmacolibrary.Drugs.ATC.V.V09AX06;

  annotation(Documentation(
    info ="<html><body><p>Florbetaben (18F) is a radioactive diagnostic agent used in positron emission tomography (PET) imaging for the visualization of beta-amyloid plaques in the brain, which is associated with Alzheimer's disease and other cognitive disorders. It is approved for clinical use in Alzheimer’s disease diagnosis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult subjects.</p><h4>References</h4><ol><li><p>Syed, YY, &amp; Deeks, E (2015). [(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment. <i>CNS drugs</i> 29(7) 605–613. DOI:<a href=&quot;https://doi.org/10.1007/s40263-015-0258-7&quot;>10.1007/s40263-015-0258-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26175116/&quot;>https://pubmed.ncbi.nlm.nih.gov/26175116</a></p></li><li><p>Rominger, A, et al., &amp; Bartenstein, P (2013). Longitudinal assessment of cerebral β-amyloid deposition in mice overexpressing Swedish mutant β-amyloid precursor protein using 18F-florbetaben PET. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 54(7) 1127–1134. DOI:<a href=&quot;https://doi.org/10.2967/jnumed.112.114660&quot;>10.2967/jnumed.112.114660</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23729696/&quot;>https://pubmed.ncbi.nlm.nih.gov/23729696</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Florbetaben18f;
